Clinical Trial Update: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease [Phase 2]

View source ↗

Summary

Phase 2 extension study evaluating long-term safety and tolerability of LAQ/5062 in relapsing remitting multiple sclerosis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• LAQ/5062

Snippet

Sponsor: Teva Pharmaceutical Industries, Ltd. | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2019-03-27